Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy.
暂无分享,去创建一个
K. Fukuda | T. Nagai | T. Yoshikawa | T. Anzai | Yuichiro Maekawa | Toshiyuki Takahashi | Atsushi Anzai | H. Kaneko | Y. Mano | Y. Nagatomo | T. Meguro | Yuji Nagatomo
[1] S. Ogawa,et al. Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction. , 2010, American journal of physiology. Heart and circulatory physiology.
[2] V. Hombach,et al. Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein? , 2009, Basic Research in Cardiology.
[3] A. Ferreira,et al. Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. , 2009, Journal of cardiac failure.
[4] T. Walther,et al. Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis During the Development of Experimental Diabetic Cardiomyopathy , 2009, Diabetes.
[5] M. Hori,et al. Impact of diabetes mellitus on rehospitalization for heart failure among survivors of acute myocardial infarction in the percutaneous coronary intervention era. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[6] Yasuhiro Hirasawa,et al. Short-term amiodarone treatment attenuates the production of monocyte cytokines and chemokines by C-reactive protein and improves cardiac function in patients with idiopathic dilated cardiomyopathy and ventricular tachycardia. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[7] E. Oda,et al. Tentative cut point of high-sensitivity C-reactive protein for a component of metabolic syndrome in Japanese. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[8] S. Yamada,et al. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. , 2008, Cardiovascular research.
[9] S. Verma,et al. Impaired endothelial function in C-reactive protein overexpressing mice. , 2008, Atherosclerosis.
[10] S. Chakrabarti,et al. PARP mediates structural alterations in diabetic cardiomyopathy. , 2008, Journal of molecular and cellular cardiology.
[11] S. Prabhu,et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. , 2008, Journal of the American College of Cardiology.
[12] C. Röcker,et al. C‐reactive protein specifically binds to Fcγ receptor type I on a macrophage‐like cell line , 2008, European journal of immunology.
[13] R. Goyal,et al. Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats , 2008, Molecular and Cellular Biochemistry.
[14] Carlos Orrego,et al. Cytokines and acute heart failure , 2008, Critical care medicine.
[15] S. Oparil,et al. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. , 2008, The American journal of pathology.
[16] Ji-nan Zhang,et al. C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes , 2008, Molecular and Cellular Biochemistry.
[17] D. Katritsis,et al. Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. , 2007, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[18] C. Tschöpe,et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy , 2007, Basic Research in Cardiology.
[19] A. Boyle,et al. Angiotensin II and the cardiac complications of diabetes mellitus. , 2007, Current pharmaceutical design.
[20] F. Qin,et al. Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. , 2007, Free radical biology & medicine.
[21] C. Tschöpe,et al. Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting Enzyme Inhibition in Experimental Diabetic Cardiomyopathy , 2007, Diabetes.
[22] E. Abel,et al. Diabetic cardiomyopathy revisited. , 2007, Circulation.
[23] U. Laufs,et al. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy , 2007, Diabetologia.
[24] John G F Cleland,et al. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. , 2007, American heart journal.
[25] W. Hsueh,et al. Recipes for creating animal models of diabetic cardiovascular disease. , 2007, Circulation research.
[26] K. Sunagawa,et al. Angiotensin II Type 1 Receptor Blocker Attenuates Myocardial Remodeling and Preserves Diastolic Function in Diabetic Heart , 2007, Hypertension Research.
[27] I. Kola,et al. Lack of the Antioxidant Enzyme Glutathione Peroxidase-1 Accelerates Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice , 2007, Circulation.
[28] K. Sunagawa,et al. Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. , 2006, American journal of physiology. Heart and circulatory physiology.
[29] S. Verma,et al. C-Reactive Protein Alters Antioxidant Defenses and Promotes Apoptosis in Endothelial Progenitor Cells , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[30] Brian Rodrigues,et al. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. , 2006, American journal of physiology. Heart and circulatory physiology.
[31] A. Hofman,et al. C-reactive protein and risk of heart failure. The Rotterdam Study. , 2006, American heart journal.
[32] S. Verma,et al. C-Reactive Protein Upregulates Receptor for Advanced Glycation End Products Expression in Human Endothelial Cells , 2006, Hypertension.
[33] C. Tschöpe,et al. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus , 2006, Diabetologia.
[34] D. Morrow,et al. Is C-reactive protein an innocent bystander or proatherogenic culprit?: The Verdict Is Still Out , 2006, Circulation.
[35] C. Yabe-Nishimura,et al. Increased gene expression of glutathione peroxidase-3 in diabetic mouse heart. , 2006, Biological & pharmaceutical bulletin.
[36] Sanjiv J. Shah,et al. High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. , 2006, Journal of cardiac failure.
[37] T. Walther,et al. Transgenic activation of the kallikrein‐kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] U. Singh,et al. C-Reactive Protein Decreases Tissue Plasminogen Activator Activity in Human Aortic Endothelial Cells: Evidence that C-Reactive Protein Is a Procoagulant , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[39] S. Oparil,et al. Estrogen Treatment Abrogates Neointima Formation in Human C-Reactive Protein Transgenic Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[40] J. Cohn,et al. C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.
[41] S. Ogawa,et al. Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. , 2005, Cardiovascular research.
[42] P. Ridker,et al. C-reactive protein comes of age , 2005, Nature Clinical Practice Cardiovascular Medicine.
[43] S. Ogawa,et al. Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction. , 2004, Journal of the American College of Cardiology.
[44] M. Rewers,et al. Elevated C-reactive protein levels in the development of type 1 diabetes. , 2004, Diabetes.
[45] M. Rutter,et al. C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.
[46] Lan Li,et al. C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice , 2004, Circulation.
[47] D. Harrison,et al. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. , 2003, Trends in pharmacological sciences.
[48] E. Edelman,et al. Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice , 2003, Circulation.
[49] S. Verma,et al. C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle , 2003, Circulation.
[50] Ren-Ke Li,et al. A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.
[51] L. Cai,et al. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. , 2002, Diabetes.
[52] A. Szalai,et al. Varied biologic functions of c-reactive protein , 2002, Immunologic research.
[53] A. Maseri,et al. Myocardial Cell Death in Human Diabetes , 2000, Circulation research.
[54] C. Mold,et al. C-Reactive Protein Binding to Murine Leukocytes Requires Fcγ Receptors1 , 2000, The Journal of Immunology.
[55] C. Mold,et al. C-reactive protein binding to murine leukocytes requires Fc gamma receptors. , 2000, Journal of immunology.
[56] D. Bharadwaj,et al. The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II , 1999 .
[57] G. Stassi,et al. Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. , 1999, Circulation.
[58] A. Koretsky,et al. Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .
[59] W. Kannel,et al. Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.